Article Archive

Page 43 of 100 · 4779 patient-friendly summaries

Weissella as an emerging probiotic candidate for IBD: current evidence, challenges, and future perspectives".
Antonie van Leeuwenhoek

Weissella as an emerging probiotic candidate for IBD: current evidence, challenges, and future perspectives".

People with IBD may be interested because the article describes a potential new probiotic genus (Weissella) that has preclinical effects on inflammation and mucosal healing—areas relevant to managing flares and...

Read Summary
Dual-Targeted Therapy in Refractory Pyoderma Gangrenosum: A Focused Systematic Review of Convergent Pathway Targeting.
Dermatology and therapy

Dual-Targeted Therapy in Refractory Pyoderma Gangrenosum: A Focused Systematic Review of Convergent Pathway Targeting.

The review aggregates published instances where combining two advanced immunomodulators was followed by improvement in pyoderma gangrenosum, a serious skin complication often seen in people with IBD. However, the...

Read Summary
Pectin and Kaolin as Adjunctive Metabolic Therapy for Maintaining Remission in Ulcerative Colitis: Biological Rationale, Current Evidence and Future Clinical Perspectives
Nutrients

Pectin and Kaolin as Adjunctive Metabolic Therapy for Maintaining Remission in Ulcerative Colitis: Biological Rationale, Current Evidence and Future Clinical Perspectives

The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...

Read Summary
GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease.
Therapeutic advances in endocrinology and metabolism

GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease.

People with IBD increasingly also have obesity and type 2 diabetes; this commentary suggests GLP-1 receptor agonists might affect not only metabolism but also inflammation and clinical outcomes relevant to IBD, which...

Read Summary
Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.
Inflammatory bowel diseases

Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.

Anti‑TL1A drugs represent a new mechanism with phase 2 signals for clinical remission and endoscopic response in both UC and Crohn's disease, plus early biomarker evidence suggesting antifibrotic effects—areas directly...

Read Summary
Reporting and representation of participant race, ethnicity, and sex in pediatric IBD clinical trials.
Inflammatory bowel diseases

Reporting and representation of participant race, ethnicity, and sex in pediatric IBD clinical trials.

Clinical trials shape available treatments and evidence; if groups of children (by race, ethnicity, or sex) are underrepresented, study results may not reflect how treatments work for them. This paper identifies...

Read Summary
Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

If you’re stable on ustekinumab for Crohn’s disease, this multicenter study found that switching to an approved biosimilar produced similar 6-month remission and safety outcomes to staying on the original product. That...

Read Summary
Comorbidity-Guided Management of Pyoderma Gangrenosum: A Clinical Guide to Emerging Therapeutic Targets.
Journal of the American Academy of Dermatology

Comorbidity-Guided Management of Pyoderma Gangrenosum: A Clinical Guide to Emerging Therapeutic Targets.

PG is often linked with IBD and other systemic conditions, so approaches that treat the underlying comorbidity can improve ulcer healing and lower relapse risk. Patients with IBD who develop PG may benefit from therapies...

Read Summary
Commentary for "Inflammatory bowel disease and cardiovascular risk: A meta-analysis".
Journal of investigative medicine : the official publication of the American Federation for Clinical Research

Commentary for "Inflammatory bowel disease and cardiovascular risk: A meta-analysis".

Cure8 found this source from Journal of investigative medicine : the official publication of the American Federation for Clinical Research, but the page could not be read reliably yet. It is tagged for Inflammatory bowel...

Read Summary
Synergy effects of Ganoderic acid A and Ganoderma lucidum polysaccharides on enhancing protection against DSS-induced colitis via gut microbiota rebalancing and inflammation suppression
Food Science and Human Wellness

Synergy effects of Ganoderic acid A and Ganoderma lucidum polysaccharides on enhancing protection against DSS-induced colitis via gut microbiota rebalancing and inflammation suppression

Researchers are exploring natural compounds that might reduce intestinal inflammation and rebalance the gut microbiome. If translatable to humans, such approaches could inform new treatments or adjunctive therapies for...

Read Summary
Figure 1 from: Georgiev S, Pampulova L, Abedinov P, Iliev R, Hadzhiev E, Petkov D (2026) How many risk factors are too many: massive pulmonary embolism in a patient with ulcerative colitis and steroid-induced vertebral fractures: a case report. Pharmacia 73: e208292. https://doi.org/10.3897/pharmacia.73.e208292
Pensoft Publishers

Figure 1 from: Georgiev S, Pampulova L, Abedinov P, Iliev R, Hadzhiev E, Petkov D (2026) How many risk factors are too many: massive pulmonary embolism in a patient with ulcerative colitis and steroid-induced vertebral fractures: a case report. Pharmacia 73: e208292. https://doi.org/10.3897/pharmacia.73.e208292

Cure8 could only read part of this source from Pensoft Publishers, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Complications.

Read Summary
How many risk factors are too many: massive pulmonary embolism in a patient with ulcerative colitis and steroid-induced vertebral fractures: a case report
Pharmacia

How many risk factors are too many: massive pulmonary embolism in a patient with ulcerative colitis and steroid-induced vertebral fractures: a case report

People with IBD who take long-term corticosteroids may have multiple overlapping risks for venous thromboembolism (prothrombotic effects of steroids, steroid-induced osteoporosis and fractures, and immobilization).

Read Summary
Figure 2 from: Georgiev S, Pampulova L, Abedinov P, Iliev R, Hadzhiev E, Petkov D (2026) How many risk factors are too many: massive pulmonary embolism in a patient with ulcerative colitis and steroid-induced vertebral fractures: a case report. Pharmacia 73: e208292. https://doi.org/10.3897/pharmacia.73.e208292
Pensoft Publishers

Figure 2 from: Georgiev S, Pampulova L, Abedinov P, Iliev R, Hadzhiev E, Petkov D (2026) How many risk factors are too many: massive pulmonary embolism in a patient with ulcerative colitis and steroid-induced vertebral fractures: a case report. Pharmacia 73: e208292. https://doi.org/10.3897/pharmacia.73.e208292

Cure8 could only read part of this source from Pensoft Publishers, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Complications.

Read Summary
Microenvironment-adaptive drug delivery systems for ulcerative colitis: from pathological constraints to rational design.
Expert opinion on drug delivery

Microenvironment-adaptive drug delivery systems for ulcerative colitis: from pathological constraints to rational design.

The review connects UC pathological features to specific drug-delivery design needs, which could guide development of therapies that reach and act effectively in inflamed colon tissue. For people with UC, better-targeted...

Read Summary
Extracts of Chrysanthemum morifolium Ramat. alleviated colitis-induced cognitive dysfunction through the BDNF/TrkB/CREB signaling pathway
Journal of Functional Foods

Extracts of Chrysanthemum morifolium Ramat. alleviated colitis-induced cognitive dysfunction through the BDNF/TrkB/CREB signaling pathway

IBD can cause cognitive and neurological symptoms. This preclinical study suggests a flavonoid-rich Chrysanthemum extract reduced colitis and related cognitive deficits in mice by changing the gut microbiota and...

Read Summary
Early Use of Anti-Tumor Necrosis Factor Therapy for Penetrating Complications in Children With Crohn's Disease: Multicenter Insight to a Challenging Clinical Problem
The American Journal of Gastroenterology

Early Use of Anti-Tumor Necrosis Factor Therapy for Penetrating Complications in Children With Crohn's Disease: Multicenter Insight to a Challenging Clinical Problem

Cure8 could only read part of this source from The American Journal of Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...

Read Summary
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
ClinicalTrials.gov

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

This study will gather real‑world effectiveness and patient‑reported outcome data for guselkumab in adults with moderate‑to‑severe Crohn’s disease or ulcerative colitis, which may help clinicians and patients understand...

Read Summary
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
ClinicalTrials.gov

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Patients and clinicians considering guselkumab for Crohn’s disease or ulcerative colitis may gain real-world evidence on how the drug performs across treatment lines and subgroups over up to 96 weeks. The study will...

Read Summary
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
ClinicalTrials.gov

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...

Read Summary
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.gov

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3 testing of guselkumab (an IL-23–targeting biologic) in moderately to severely active ulcerative colitis could expand treatment options if the trial meets its endpoints and shows an acceptable safety profile. The...

Read Summary
Large language models with supervised fine-tuning for inflammatory bowel disease diagnosis and prognosis
World Journal of Gastroenterology

Large language models with supervised fine-tuning for inflammatory bowel disease diagnosis and prognosis

AI tools are being tailored to IBD care; this study suggests supervised fine-tuned LLMs may help with patient communication and workflow but currently lack reliable diagnostic accuracy. Patients and clinicians should...

Read Summary
The regulatory role of post-translational modifications in the pathogenesis of ulcerative colitis
Molecular Biology Reports

The regulatory role of post-translational modifications in the pathogenesis of ulcerative colitis

Understanding PTMs may help researchers identify new biomarkers or therapeutic targets for ulcerative colitis, which could eventually lead to better treatments or tests. For people with UC, this explains part of why...

Read Summary
Integrated multi-omics, network pharmacology, and experimental validation reveal the protective mechanisms of curcumol against DSS-induced ulcerative colitis
Frontiers in Immunology

Integrated multi-omics, network pharmacology, and experimental validation reveal the protective mechanisms of curcumol against DSS-induced ulcerative colitis

The study identifies a plant-derived compound (curcumol) that reduced inflammation, mucosal injury, and some microbiome/metabolome disturbances in a mouse model of ulcerative colitis and links these effects to...

Read Summary
Extracts of Gleditsia sinensis Lam. thorn ameliorates ulcerative colitis through PPARγ/GPX4 pathway-mediated inhibition of enterocyte ferroptosis
World Journal of Gastroenterology

Extracts of Gleditsia sinensis Lam. thorn ameliorates ulcerative colitis through PPARγ/GPX4 pathway-mediated inhibition of enterocyte ferroptosis

This study reports preclinical evidence that an herbal extract (EGST) reduced inflammation and epithelial cell ferroptosis in a mouse model of ulcerative colitis and in cell experiments, implicating the PPARγ/GPX4...

Read Summary
A novel inflammatory bowel disease registry powered by artificial intelligence and natural language processing.
PLOS digital health

A novel inflammatory bowel disease registry powered by artificial intelligence and natural language processing.

Registries that automatically extract clinical data with AI/NLP can speed research, help identify patient cohorts for studies or trials, and may eventually support better clinical decision-making for people with IBD....

Read Summary
Plasma proteomic signatures associated with ulcerative colitis risk in overweight/obesity individuals: a UK Biobank study
Scientific Reports

Plasma proteomic signatures associated with ulcerative colitis risk in overweight/obesity individuals: a UK Biobank study

If you have overweight or obesity, this study suggests measurable blood proteins linked to inflammation may be associated with higher future risk of ulcerative colitis. Identifying such markers could help research on...

Read Summary
Mechanistic Insights into the Anti-Inflammatory Activity of a Sulfated α-Glucan (VpG) from Volutharpa ampullacea perryi
Macromol

Mechanistic Insights into the Anti-Inflammatory Activity of a Sulfated α-Glucan (VpG) from Volutharpa ampullacea perryi

Researchers are exploring new anti-inflammatory molecules for ulcerative colitis. Mechanistic data showing inhibition of macrophage M1 polarization, MAPK signaling, and antioxidant activity may help prioritize VpG for...

Read Summary
Oral Nanomicelle‐Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment
Advanced Science

Oral Nanomicelle‐Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment

Butyrate supports intestinal health and is often low in IBD. A single oral compound that reliably restores luminal butyrate could — if proven safe and effective in humans — offer a new way to treat ulcerative colitis or...

Read Summary